Agenus’ (AGEN) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Agenus (NASDAQ:AGEN) in a research note released on Monday morning,Benzinga reports. Chardan Capital currently has a $40.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on AGEN. B. Riley Financial reaffirmed a “buy” rating and set a $14.00 price objective (up from $8.00) on shares of Agenus in a research report on Thursday, July 30th. Weiss Ratings cut shares of Agenus from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, August 21st. Rodman & Renshaw began coverage on Agenus in a report on Monday, September 28th. They set a “buy” rating and a $19.00 target price for the company. Wall Street Zen downgraded shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Agenus Stock Up 4.4%

Shares of Agenus stock opened at $8.73 on Monday. The stock has a market cap of $394.25 million, a P/E ratio of 3.38 and a beta of 1.31. Agenus has a 12-month low of $2.71 and a 12-month high of $10.31. The business’s 50 day moving average is $7.81 and its 200-day moving average is $5.19.

Agenus (NASDAQ:AGEN) last released its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $34.52 million during the quarter, compared to the consensus estimate of $34.00 million. Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. On average, sell-side analysts expect that Agenus will post -0.3 EPS for the current year.

Institutional Trading of Agenus

Hedge funds have recently made changes to their positions in the company. Globeflex Capital L P acquired a new position in shares of Agenus in the second quarter valued at approximately $1,281,000. Bank of New York Mellon Corp bought a new position in Agenus during the second quarter worth $311,000. Bank of America Corp DE grew its holdings in Agenus by 796.7% during the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after acquiring an additional 105,536 shares during the period. Ovata Capital Management Ltd bought a new position in shares of Agenus in the 4th quarter worth about $97,000. Finally, Redwood Family Wealth LLC acquired a new position in shares of Agenus in the 4th quarter valued at about $44,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.